Literature DB >> 29566747

Correction to: Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-κB signaling pathway in vivo and in vitro.

Bo Liu1,2, Fengxia Ding3,2, Dong Hu2, Yu Zhou2, Chunlan Long2, Lianju Shen2, Yuanyuan Zhang4, Deying Zhang5,6, Guanghui Wei1.   

Abstract

The original article [1] contains an error whereby the corresponding authorship is mistakenly designated to the author Fengxia Ding.

Entities:  

Year:  2018        PMID: 29566747      PMCID: PMC5865288          DOI: 10.1186/s13287-018-0845-x

Source DB:  PubMed          Journal:  Stem Cell Res Ther        ISSN: 1757-6512            Impact factor:   6.832


Erratum

The original article [1] contains an error whereby the corresponding authorship is mistakenly designated to the author Fengxia Ding. The authors would like to clarify that Deying Zhang is the actual corresponding author for this manuscript, and all queries concerning the manuscript should be addressed to deyingzhang@126.com instead.
  1 in total

1.  Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-κB signaling pathway in vivo and in vitro.

Authors:  Bo Liu; Fengxia Ding; Dong Hu; Yu Zhou; Chunlan Long; Lianju Shen; Yuanyuan Zhang; Deying Zhang; Guanghui Wei
Journal:  Stem Cell Res Ther       Date:  2018-01-12       Impact factor: 6.832

  1 in total
  2 in total

1.  An Integration of Network Pharmacology and Experimental Verification to Investigate the Mechanism of Guizhi to Treat Nephrotic Syndrome.

Authors:  Dan He; Qiang Li; Guangli Du; Guofeng Meng; Jijia Sun; Shaoli Chen
Journal:  Front Pharmacol       Date:  2021-12-02       Impact factor: 5.810

2.  Human umbilical cord-derived mesenchymal stem cells improve chronic pancreatitis in rats via the AKT-mTOR-S6K1 signaling pathway.

Authors:  Lijun Kong; Xiangxiang Xu; Hewei Zhang; Yi Zhou; Hongjian Huang; Bicheng Chen; Zhenxu Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.